Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Exploratory outcomes - Evaluate the changes in Pyruvate dehydrogenase activation between oleuropein and placebo groups following 1 single dose |
measured by western blotting |
Chronic effect after 36 days of intake |
|
Primary |
Exploratory outcomes - Evaluate the changes in Pyruvate dehydrogenase activation between oleuropein and placebo groups following 1 single dose |
measured by biochemical assay analysis |
Acute effect after first product intake + chronic effect after 36 days of intake |
|
Primary |
Exploratory outcomes - to evaluate the changes Mitocondrial respiration between oleuropein and placebo groups following 1 single dose |
measured the rates of oxygen consumption (respiration or JO2) using Oroboros Oxygraph 2K systems with physiological ADP concentrations using permeabilized muscle fibres. |
Acute effect after first product intake + chronic effect after 36 days of intake |
|
Primary |
Exploratory outcomes- to evaluate the changes of fatigue between oleuropein and placebo groups following 1 single dose |
measured using Biodex dynamometer |
After 4 weeks of supplementation |
|
Primary |
Exploratory outcomes - to evaluate the changes of fatigue between oleuropein and placebo groups |
measured using Biodex dynamometer |
Chronic effect (after 29 days of supplementation) |
|
Primary |
Exploratory outcomes - to evaluate the changes of Pyruvate dehydrogenase activation between oleuropein and placebo groups |
measured by western blotting |
Chronic effect (after 36 days of supplementation) |
|
Primary |
Exploratory outcomes - to evaluate the changes of Pyruvate dehydrogenase activation between oleuropein and placebo groups |
measured by biochemical assay analysis |
Chronic effect (after 36 days of supplementation) |
|
Primary |
Exploratory outcomes - To evaluate the changes of Mitochondrial respiration between oleuropein and placebo groups |
measured the rates of oxygen consumption (respiration or JO2) using Oroboros Oxygraph 2K systems with physiological ADP concentrations using permeabilized muscle fibres. |
Chronic effect (after 36 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes of whole body respiratory exchange ratio (RER) between oleuropein and placebo groups following 1 single dose |
measured the oxygen and carbon dioxide volume using indirect calorimetry with ventilated hood |
Acute effect after first product intake+ chronic effect after 36 days of intake |
|
Secondary |
Exploratory outcomes - to evaluate the changes of oleuropein metabolites between oleuropein and placebo groups following 1 single dose |
measured by the analyze of oleuropein metabolites in blood |
Acute effect after first product intake + chronic effect after 36 days of intake |
|
Secondary |
Exploratory outcomes - to evaluate the changes of glucose concentration between oleuropein and placebo groups following 1 single dose |
measured by the analyze glucose in blood |
Acute effect after first product intake + chronic effect after 36 days of intake |
|
Secondary |
Exploratory outcomes - to evaluate the changes Blood glucose, insulin, free fatty acid concentrations -between oleuropein and placebo groups following 1 single dose |
measured by the analyze of Insulin in blood |
Acute effect after first product intake + chronic effect after 36 days of intake |
|
Secondary |
Exploratory outcomes - to evaluate the changes of free fatty acid concentration between oleuropein and placebo groups following 1 single dose |
measured by the analyze of free fatty acid concentration (FFA, TG) in blood |
Acute effect after first product intake + chronic effect after 36 days of intake |
|
Secondary |
Exploratory outcomes - to evaluate the changes of blood pressure between oleuropein and placebo groups following 1 single dose |
measured using automated inflatable cuff |
Acute effect after first product intake + chronic effect after 36 days of intake |
|
Secondary |
Exploratory outcomes - to evaluate the changes of anti-inflammatory markers between oleuropein and placebo groups |
measured by the analyze of anti-inflammatory markers in blood |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes of Antioxidant markers between oleuropein and placebo groups |
measured by the analyze of antioxidant markers in blood |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes in glucose concentration between oleuropein and placebo groups |
measured by the analyze glucose in blood |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes of insulin concentration between oleuropein and placebo groups |
measured by the analyze of insulin in blood |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes of free fatty acid concentration between oleuropein and placebo groups |
measured by the analyze of free fatty acid concentration (FFA, TG) in blood |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes in Mood state and quality of life between oleuropein and placebo groups |
measured with the World Health Organisation quality of life questionnaire (WHOQOL-BREF) (rating 0 for 'not at all' and 5 for 'an extreme amount') |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes in Mood state and quality of life between oleuropein and placebo groups |
measured with the Profile of Mood States - short-form (POMS-SF) - scale (rating 0 for 'not at all' and 4 for 'extremely') |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes in Mood state and quality of life between oleuropein and placebo groups |
measured with the Quality of Life (QoL) questionnaires |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes in the fatigue perception and mood state pre/post Biodex measurement between oleuropein and placebo groups |
measured with the current mood questionnaire (rating 0 for 'not at all' - 4 for 'extremely') |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes in the fatigue perception and mood state pre/post Biodex measurement between oleuropein and placebo groups |
RPE visual analog scale Questionnaire - BORG scale (6 for 'no exertion - 20 for 'maximal exertion' |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes to evaluate the changes in body composition between oleuropein and placebo groups |
measure the whole body muscle and fat content using Magnetic resonance imaging (MRI) |
Chronic effect (after 29 days of supplementation) |
|
Secondary |
Exploratory outcomes - Whole body respiratory exchange ratio - To evaluate the changes of Whole body respiratory exchange ratio (RER) between oleuropein and placebo groups |
measure the oxygen and dioxygen volume using Indirect calorimetry with ventilation hood |
Chronic effect (after 36 days of supplementation) |
|
Secondary |
Exploratory outcomes - To evaluate the changes of oleuropein metabolites between oleuropein and placebo groups |
measure by analyzing Oleuropein metabolites in blood |
Chronic effect (after 36 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes of molecular signalling, and protein and mRNA levels of regulators of muscle metabolism between oleuropein and placebo groups |
measured by analyzing RNAseq and MS-based proteomics |
Chronic effect (after 36 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes of molecular signalling, and protein and mRNA levels of regulators oleuropein and placebo groups |
measured using Western Blot |
Chronic effect (after 36 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes of molecular signalling, and protein and mRNA levels of regulators oleuropein and placebo groups |
measured by analyzing polymerase chain reaction |
Chronic effect (after 36 days of supplementation) |
|
Secondary |
Exploratory outcomes - to evaluate the changes in Strength between oleuropein and placebo groups |
measured using biodex dynanometer |
After 4 weeks of supplementation |
|
Secondary |
Exploratory outcomes to evaluate the changes of strenght between oleuropein |
measured using biodex dynanometer |
Chronic effect (after 29 days of supplementation) |
|